AccessibilityHelpAbout Us
Hls Therapeutics logo

Hls Therapeutics(TSX) HLS

Market CapCA$124.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-63%
5 Year-77%
1 Year-26%
1 Month+10%
CA$4.02
+2.03%
+0.08Today
Hls Therapeutics last closing stock price
MetricPriceDate
Last closeCAD 4.022026-09-25
Hls Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.81%CAD 3.912026-09-18
1 month+10.14%CAD 3.652026-08-26
3 month-2.9%CAD 4.142026-06-26
Year to date-16.6%CAD 4.822025-12-31
1 year-25.83%CAD 5.422025-09-25
3 year-23.43%CAD 5.252023-09-26
5 year-76.93%CAD 17.422021-09-24
Since inception-62.86%CAD 10.822018-03-15

Hls Therapeutics Financials at a Glance

Market Cap

CA$124.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$55.89M

Net Income (TTM)

-$8.53M

EPS (TTM)

-CA$0.38

P/E Ratio

-10.66

Dividend

CA$0.00

Beta (Volatility)

0.48 (Low)

Price

CA$4.02

Volume

370,338

Open

CA$4.00

Previous Close

CA$4.02

Daily Range

CA$3.94 - CA$4.04

52-Week Range

CA$3.56 - CA$5.77

Estimated Earnings Date

Nov 12, 2026

HLS News

A couple administering a blood pressure test

This Pharmaceutical Company Just Got a Major Boost

Jeffrey LittleAug 27, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hls Therapeutics

HLS Therapeutics Inc. is a specialized pharmaceutical company focused on acquiring and commercializing medicinal products in the central nervous system (CNS) and cardiovascular (CV) sectors. The company operates in Canada, the United States, and international markets, offering a range of innovative therapies.

Products and Services
  • Clozaril, an atypical antipsychotic for schizophrenia treatment
  • Vascepa, an icosapent ethyl capsule formulation
  • PERSERIS, an injectable risperidone product for schizophrenia
Growth Outlook
  • Recent quarterly revenue increased to CAD 14.29 million, showing strong market demand
  • Expansion into international markets is expected to drive future growth
  • Continued investment in product development aims to enhance the therapeutic portfolio
Financial Highlights
  • Trailing twelve months (TTM) revenue of CAD 54.5 million reflects a solid performance
  • Operating cash flow of CAD 6.36 million in Q1 2026 indicates operational efficiency
  • Gross profit margin improved to 42.9% in Q2 2026, showcasing effective cost management
HLS Therapeutics Inc. has established itself as a key player in the pharmaceutical industry, particularly in the CNS and CV sectors. The company's focus on innovative therapies positions it well for future growth, especially as it expands its market reach. Recent financial performance highlights a positive trend, with increasing revenues and improving profit margins. The operational efficiency demonstrated in cash flow metrics further supports the company's potential for sustainable growth. Investors may find HLS Therapeutics Inc. an intriguing opportunity within the healthcare sector.
AI Generated • Sep 7, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

85

CEO

Craig Millian, MBA

Website

www.hlstherapeutics.com

Headquarters

Etobicoke, ON M9W 6L2, CA

HLS Financials

Key Financial Metrics (TTM)

Gross Margin

61.41%

Operating Margin

-7.95%

Net Income Margin

-15.20%

Return on Equity

-14.43%

Return on Capital

-3.75%

Return on Assets

-6.66%

Earnings Yield

-9.38%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$124.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

30.94M

Volume

370.34K

Avg. Volume

52.85K

Financials (TTM)

Gross Profit

$28.87M

Operating Income

-$4.44M

EBITDA

$17.33M

Operating Cash Flow

$18.13M

Capital Expenditure

-$695.45K

Free Cash Flow

$17.43M

Cash & ST Invst.

$13.71M

Total Debt

$41.84M

Hls Therapeutics Performance Analysis

Hls Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 80,021,0286.4%
20232023-12-31USD 85,130,1566.4%
20242024-12-31USD 77,565,855-8.9%
20252025-12-31USD 77,549,515-0.0%
Hls Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-4.7%
Q42025-12-3114.2%
Q12026-03-31-18.0%
Q22026-06-3013.0%
Hls Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.9585.4%
20232023-12-31USD -1.1521.6%
20242024-12-31USD -0.85-26.6%
20252025-12-31USD -0.55-34.9%
Hls Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-33.3%
Q42025-12-3163.9%
Q12026-03-31-65.6%
Q22026-06-3055.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$14.29M

+0.9%

Gross Profit

$6.13M

-47.4%

Gross Margin

42.90%

N/A

Market Cap

CA$124.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$1.46M

N/A

Employees

85

N/A

Net Income

-$993.67K

+63.7%

EBITDA

$4.26M

-9.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$13.71M

+12.8%

Total Debt

$41.84M

-24.7%

Accounts Receivable

$8.49M

-6.1%

Inventory

$6.13M

-10.2%

Long Term Debt

$37.25M

-24.6%

Short Term Debt

$4.59M

-25.4%

Return on Assets

-6.66%

N/A

Return on Invested Capital

-4.50%

N/A

Free Cash Flow

$2.84M

-19.2%

Operating Cash Flow

$2.84M

-38.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LOVE.VCannara Biotech Inc.
CA$1.89+6.18%
RX.VBioSyent Inc.
CA$16.61+0.36%
CRDL.TOCardiol Therapeutics Inc.
CA$2.43+0.00%
XLY.TOAuxly Cannabis Group Inc.
CA$3.63+3.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$32.43-3.57%
NOKNokia
$10.39-0.38%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$151.45+3.50%
NVDANvidia
$225.07+0.22%

Questions About HLS

What is the current price of Hls Therapeutics?

Hls Therapeutics is trading at CA$4.02 per share.

What is the 52-week range for Hls Therapeutics?

Over the past 52 weeks, Hls Therapeutics has traded between CA$3.56 and CA$5.77.

How much debt does Hls Therapeutics have?

As of the most recent reporting period, Hls Therapeutics reported total debt of $59.45M.

How much cash does Hls Therapeutics have on hand?

Hls Therapeutics reported $19.48M in cash and cash equivalents in its most recent financial results.

What is Hls Therapeutics’s dividend yield?

Hls Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services